Safety and Implementation of Ketamine, Psilocybin, and rTMS for TRD: 2026 Review

Review Highlights: Current Evidence and Clinical Promise

A November 2026 narrative review (OpenAlex W7226030337) synthesizes the state of evidence for rapid-acting and psychedelic-assisted interventions in treatment-resistant depression (TRD), focusing on ketamine, esketamine, psilocybin, and advanced repetitive transcranial magnetic stimulation (rTMS). The review confirms that ketamine and esketamine provide rapid antidepressant effects in carefully selected TRD patients, with esketamine supported by randomized controlled trials (RCTs) for relapse prevention among responders. Psilocybin-assisted therapy demonstrates promising short-term efficacy, but long-term outcomes and generalizability remain uncertain. Accelerated and connectivity-guided rTMS protocols may reduce treatment burden, though evidence is still emerging.

Importantly, the review emphasizes that acute symptom improvement does not guarantee sustained remission or functional recovery. The authors note that real-world readiness for these interventions depends on more than initial efficacy, highlighting the need for robust safety monitoring, individualized maintenance strategies, and implementation research.

Mechanisms, Maintenance, and Monitoring: What We Know

Rapid-acting antidepressants such as ketamine and esketamine act primarily via N-methyl-D-aspartate (NMDA) receptor antagonism, leading to downstream effects on glutamate signaling and synaptic plasticity. Psilocybin, a classic psychedelic, exerts its effects through serotonin 5-HT2A receptor agonism, with both pharmacological and psychological mechanisms contributing to antidepressant outcomes. rTMS and its accelerated or connectivity-guided variants modulate cortical excitability and network function through electromagnetic pulses.

While these mechanisms offer new avenues for patients unresponsive to traditional antidepressants, the review points out that maintenance of benefit is variable. Esketamine has the most robust data for ongoing relapse prevention, but requires frequent administration and long-term safety data are limited. Ketamine's maintenance protocols are less standardized, with concerns about cognitive effects and potential for misuse. Psilocybin studies generally focus on acute or short-term outcomes, with little data on repeated dosing or sustained remission. rTMS protocols are evolving, with accelerated schedules showing promise but lacking long-term comparative studies.

Policy and Research Implications: Toward Real-World Integration

The review argues that sustainable progress in TRD treatment requires more than proof of acute efficacy. Standardized adverse event reporting, individualized care planning, and longitudinal assessment of patient-centered outcomes are essential for safe and equitable clinical adoption. Implementation research—studying how these therapies can be delivered effectively in diverse, real-world settings—remains a critical gap.

• Patient selection: Identifying who benefits most from each intervention is still an open question, with most studies excluding patients with complex comorbidities or high suicide risk.
• Adverse event surveillance: Systematic, long-term safety monitoring is lacking, particularly for repeated or maintenance dosing of ketamine and psilocybin.
• Relapse prevention: Only esketamine has RCT evidence for relapse prevention, and even this is limited to selected responders.
• Affordability and service capacity: High costs, need for specialized staff, and infrastructure requirements limit access, especially outside major academic centers.

A non-obvious insight from the review is that implementation challenges—such as workforce training, regulatory compliance, and integration with existing mental health services—may ultimately determine the real-world impact of these therapies more than pharmacological differences alone.

Risks, Unknowns, and Failure Modes

Despite their promise, these emerging treatments carry substantial risks and knowledge gaps. Long-term safety data are sparse, especially for repeated administration of ketamine and psilocybin. There are concerns about cognitive impairment, dissociation, misuse potential, and psychological destabilization, particularly in unsupervised or poorly monitored settings. For rTMS, durability of response and optimal protocols for maintenance remain unclear.

Another underappreciated failure mode is the risk of inequitable access: without deliberate policy and infrastructure planning, these advanced therapies may remain available only to a privileged subset of patients, exacerbating existing disparities in mental health care.

Outlook: Next Steps for Research and Practice

Future progress in TRD treatment will depend on closing gaps in long-term safety, maintenance strategies, and implementation science. The review calls for:

• Standardized, longitudinal safety and outcome monitoring across all interventions
• Development and testing of individualized maintenance protocols
• Implementation research to address workforce, regulatory, and access barriers
• Inclusion of diverse, real-world patient populations in future trials

For researchers, funders, and policymakers, the key message is that demonstrating rapid antidepressant effects is only the first step. Ensuring these interventions deliver durable, safe, and equitable benefits in routine practice will require coordinated efforts across clinical research, health systems, and policy domains.

By Dr. Alex Chen, MD, PhD. Reviewed by Dr. Priya Raman, MD, MSc on 2026-11-14. Research based on primary literature and regulatory documents; see OpenAlex W7226030337 for source review.